La chaîne d'options affiche les données clés des options sur actions de NextCure à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour NextCure..

NextCure (NASDAQ:NXTC) Stock, Chaîne d'Options

NEXTCURE INC

NextCure

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Inc

Health Care

Press Releases

General

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Earnings

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

News

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NXTC

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Aptevo Therapeutics

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

iBio

Kairos Pharma

Lunai Bioworks

Leap Therapeutics

Lisata Therapeutics

Moleculin Biotech

MetaVia

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Rallybio

SAB Biotherapeutics

Synlogic

Tharimmune

Exicure

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

Piper Sandler

HC Wainwright & Co.

Needham

Comments

NextCure

NextCure (NXTC) Options

NextCure (NASDAQ:NXTC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL